A Phase 3 Multi-Center Randomized Double-Blind Trial to Evaluate The Efficacy and Safety of Aficamten Compared To Placebo in Adults with Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Hypertrophic Cardiomyopathy
  • Age: Between 18 Year(s) - 85 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Body mass index < 40 kg/m2.
    2. Diagnosed with nHCM.
    3. New York Heart Association (NYHA) class II or III.

You may not be eligible for this study if the following are true:

    1. Inability to exercise on a treadmill or bicycle.
    2. History of syncope, symptomatic ventricular arrhythmia, or sustained ventricular tachyarrhythmia with exercise within 3 months prior to screening .
    3. History of resistant hypertension.
    4. Received prior treatment with aficamten.
    5. Undergone septal reduction therapy < 6 months prior to screening.
    6. Is being considered for or is likely to be considered for heart transplant listing or left ventricular assist device placement during the study period.
    7. Recipient of a major organ transplant (e.g. heart, lung, liver, bone marrow, renal) or anticipated transplantation.
    8. Inability to tolerate cardiac MRI.
    9. Has an implantable cardioverter defibrillator (ICD).
    10. Has a cardiac pacemaker.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.